FR15C0036I1 - - Google Patents

Info

Publication number
FR15C0036I1
FR15C0036I1 FR15C0036C FR15C0036I1 FR 15C0036 I1 FR15C0036 I1 FR 15C0036I1 FR 15C0036 C FR15C0036 C FR 15C0036C FR 15C0036 I1 FR15C0036 I1 FR 15C0036I1
Authority
FR
France
Prior art keywords
disclosed
synthesis
novel
ceramide
udp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23182463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR15C0036(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR15C0036I1 publication Critical patent/FR15C0036I1/fr
Application granted granted Critical
Publication of FR15C0036I2 publication Critical patent/FR15C0036I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrrole Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Disclosed is a novel enantiomeric synthesis of ceramide-like inhibitors of UDP-glucose: N -acylsphingosine glucosyltransferase. Also disclosed are novel intermediates formed during the synthesis.
FR15C0036C 2001-07-16 2015-05-13 AN N-ACYLSPHINGOSINE GLYCOSYLTRANSFERASE INHIBITOR Active FR15C0036I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30581401P 2001-07-16 2001-07-16
PCT/US2002/022659 WO2003008399A1 (en) 2001-07-16 2002-07-16 Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors

Publications (2)

Publication Number Publication Date
FR15C0036I1 true FR15C0036I1 (en) 2015-06-26
FR15C0036I2 FR15C0036I2 (en) 2016-05-27

Family

ID=23182463

Family Applications (1)

Application Number Title Priority Date Filing Date
FR15C0036C Active FR15C0036I2 (en) 2001-07-16 2015-05-13 AN N-ACYLSPHINGOSINE GLYCOSYLTRANSFERASE INHIBITOR

Country Status (16)

Country Link
US (11) US6855830B2 (en)
EP (3) EP1409467B1 (en)
JP (6) JP5038582B2 (en)
AT (2) ATE554082T1 (en)
BE (1) BE2015C029I2 (en)
BR (3) BR122015016313B8 (en)
CA (1) CA2453978C (en)
CY (1) CY2015028I2 (en)
DK (3) DK2266968T3 (en)
ES (3) ES2395463T3 (en)
FR (1) FR15C0036I2 (en)
HK (2) HK1132267A1 (en)
IL (3) IL159905A0 (en)
LU (1) LU92717I2 (en)
PT (3) PT2266968E (en)
WO (1) WO2003008399A1 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890949B1 (en) * 1999-07-09 2005-05-10 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
JP2004531478A (en) 2001-01-10 2004-10-14 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Aminoceramide-like compounds and methods of use for therapeutic purposes
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
PT2266968E (en) 2001-07-16 2013-02-25 Genzyme Corp Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors
US6835831B2 (en) * 2001-11-26 2004-12-28 Genzyme Corporation Diastereoselective synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
US20060217560A1 (en) * 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
US6916802B2 (en) * 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
JP4195411B2 (en) * 2004-04-12 2008-12-10 セイコーエプソン株式会社 Method for manufacturing organic electroluminescence device
US8003617B2 (en) * 2004-11-10 2011-08-23 Genzyme Corporation Methods of treating diabetes mellitus
CA2595519C (en) * 2005-01-26 2013-10-29 Allergan, Inc. Methods of using as analgesics 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
SI2032134T1 (en) 2006-05-09 2015-10-30 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
ES2744574T3 (en) 2007-01-18 2020-02-25 Genzyme Corp Oligosaccharides comprising an aminooxy group and conjugates thereof
US8173683B2 (en) 2007-03-06 2012-05-08 Allergan, Inc. Methods for treating cognitive disorders
US9314466B2 (en) 2007-03-06 2016-04-19 Allergan, Inc. Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
US20140179925A1 (en) 2009-09-04 2014-06-26 Allergan, Inc. Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
US8623891B2 (en) * 2007-03-06 2014-01-07 Allergan, Inc. Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
WO2008150486A2 (en) 2007-05-31 2008-12-11 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
KR101640263B1 (en) 2007-10-05 2016-07-15 젠자임 코포레이션 Method of treating polycystic kidney diseases with ceramide derivatives
US8168631B2 (en) 2008-02-05 2012-05-01 Allergan, Inc. 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity
WO2010014554A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
JP2012504608A (en) 2008-10-03 2012-02-23 ジェンザイム コーポレーション 2-Acylaminopropanol-type glucosylceramide synthase inhibitor
BR122020010601B8 (en) 2008-12-16 2021-07-27 Genzyme Corp protein-oligosaccharide conjugates, their uses, and pharmaceutical compositions
LT2796457T (en) * 2009-11-27 2016-09-12 Genzyme Corporation Genz 112638 for treating gaucher or fabry disease in combination therapy
US8880109B2 (en) 2010-04-16 2014-11-04 Kyocera Corporation Radio communication system, high-power base station, low-power base station, and communication control method
BR112013026976A2 (en) 2011-04-22 2019-09-24 Genzyme Corp alpha accelerated modified modified acid glucosity
US8961959B2 (en) 2011-10-17 2015-02-24 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
EP2968268B1 (en) 2013-03-15 2020-07-29 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
JP6537500B2 (en) 2013-09-20 2019-07-03 ビオマリン プハルマセウトイカル インコーポレイテッド Glucosylceramide synthase inhibitors for the treatment of diseases
WO2015059679A1 (en) * 2013-10-25 2015-04-30 Dr. Reddy's Laboratories Limited Improved process for the preparation of eliglustat
JP6526652B2 (en) 2013-10-29 2019-06-05 ビオマリン プハルマセウトイカル インコーポレイテッド N- (1-hydroxy-3- (pyrrolidinyl) propan-2-yl) pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors
US10202340B2 (en) 2015-02-02 2019-02-12 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
CN104557851B (en) * 2015-02-10 2017-04-05 苏州明锐医药科技有限公司 The preparation method of Yi Lusita
WO2016166170A1 (en) 2015-04-14 2016-10-20 Sandoz Ag Crystalline eliglustat hydrochloride
WO2017068496A1 (en) * 2015-10-20 2017-04-27 Dr. Reddy' S Laboratories Limited Improved process for the preparation of eliglustat and its salts
CN105646442A (en) * 2015-10-27 2016-06-08 北京凯莱天成医药科技有限公司 Preparation method of eliglustat
AU2017251256B2 (en) 2016-04-11 2022-06-09 Inserm - Institut National De La Santé Et De La Recherche Médicale Inhibitors of glucosylceramide degradation in the treatment of diseases of the motor units
CN106349210A (en) * 2016-08-24 2017-01-25 北京阳光诺和药物研究有限公司 Method for preparing tartrate EGS
CN106967042B (en) * 2017-03-21 2020-08-14 浙江奥翔药业股份有限公司 Synthesis method of eligerlat and intermediate compound thereof
CN108822072B (en) * 2017-04-11 2021-01-12 中国医学科学院药物研究所 Method for preparing Elligusurgitol
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof
WO2018225085A1 (en) 2017-06-05 2018-12-13 Cipla Limited Stable solid dispersions of eliglustat hemitartrate
CN116139130A (en) 2017-12-15 2023-05-23 建新公司 Method for treating gaucher disease
US12064414B2 (en) 2017-12-20 2024-08-20 Aizant Drug Research Solutions Private Limited. Stable amorphous Eliglustat premix and process for the preparation thereof
CN111217791B (en) * 2018-11-27 2024-02-02 广东东阳光药业股份有限公司 Ibrutin intermediate and preparation method thereof
EP3941917A4 (en) * 2019-03-22 2022-12-21 Piramal Pharma Limited An improved process for the preparation of eliglustat and its intermediate
WO2020193746A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival of patients suffering from melanoma
US11220479B2 (en) 2019-10-23 2022-01-11 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
WO2021214771A1 (en) 2020-04-23 2021-10-28 The Israel Institute of Biological Research (IIBR) Glucosylceramide synthase inhibitors for prevention and treatment of viral diseases
WO2021221953A1 (en) 2020-04-28 2021-11-04 The Regents Of The University Of Michigan Pyridine inhibitors of glucosylceramide synthase and therapeutic methods using the same
CN116120274A (en) 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 Pharmaceutically acceptable salts of irinotecan and crystalline forms thereof
EP4201403A1 (en) 2021-12-21 2023-06-28 Som Innovation Biotech, S.L. Compounds tirapazamine and quazinone for use in the treatment of gm2 gangliosidoses

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3522475A1 (en) 1985-06-22 1987-01-02 Kali Chemie Pharma Gmbh NEW AROMATIC COMPOUNDS, THEIR PRODUCTION AND USE
JPH0416856A (en) 1990-05-10 1992-01-21 Canon Inc Positively chargeable nonmagnetic toner
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
HUT73527A (en) 1993-08-13 1996-08-28 Seikagaku Kogyo Co Ltd Remedy for nervous diseases
US5631394A (en) * 1994-02-02 1997-05-20 The Liposome Company, Inc. Pharmaceutically active ceramide-related compounds
CA2192555C (en) * 1994-06-10 2005-01-11 Jinichi Inokuchi 2-acylaminopropanol compound and medicinal composition
FR2734819B1 (en) 1995-05-31 1997-07-04 Adir NOVEL COMPOUNDS OF PIPERAZINE, PIPERIDINE AND 1,2,5,6-TETRAHYDROPYRIDINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US20030073680A1 (en) * 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO1997010817A1 (en) 1995-09-20 1997-03-27 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6255336B1 (en) 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6890949B1 (en) 1999-07-09 2005-05-10 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
NO965193L (en) 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminal alcohol derivative and process for its preparation
JP3993908B2 (en) * 1995-12-08 2007-10-17 生化学工業株式会社 Amino alcohol derivative and method for producing the derivative
JP4140984B2 (en) 1995-12-20 2008-08-27 生化学工業株式会社 Drug with differentiation-inducing action
US5916802A (en) * 1997-02-19 1999-06-29 Fritz Berthold Device for measuring ATP
US5972928A (en) 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (en) 1997-05-23 2008-01-23 生化学工業株式会社 Amino alcohol derivatives and pharmaceuticals containing the same
JP4176170B2 (en) 1997-06-06 2008-11-05 生化学工業株式会社 Medicine containing amino alcohol derivative and therapeutic agent for abnormal proliferative disease
AU756008B2 (en) * 1998-07-27 2003-01-02 Johns Hopkins University, The Methods for treating conditions modulated by lactosylceramide
US7148251B2 (en) 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20040260099A1 (en) 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20020198240A1 (en) * 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
JP2004531478A (en) * 2001-01-10 2004-10-14 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Aminoceramide-like compounds and methods of use for therapeutic purposes
PT2266968E (en) * 2001-07-16 2013-02-25 Genzyme Corp Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors
US20060217560A1 (en) 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
US6916802B2 (en) * 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
SI2032134T1 (en) * 2006-05-09 2015-10-30 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis

Also Published As

Publication number Publication date
EP2067775B1 (en) 2012-04-25
CA2453978C (en) 2011-10-11
JP6182254B2 (en) 2017-08-16
ES2395463T3 (en) 2013-02-15
DK1409467T3 (en) 2012-07-16
EP1409467B1 (en) 2012-04-18
PT2266968E (en) 2013-02-25
JP4708073B2 (en) 2011-06-22
CY2015028I1 (en) 2016-07-27
BR122015016313B1 (en) 2019-04-16
ATE554082T1 (en) 2012-05-15
IL159905A0 (en) 2004-06-20
US20210171507A1 (en) 2021-06-10
DK2067775T3 (en) 2012-07-16
EP2266968A3 (en) 2011-05-18
BE2015C029I2 (en) 2021-07-19
US9546161B2 (en) 2017-01-17
JP2013136618A (en) 2013-07-11
ATE555102T1 (en) 2012-05-15
US20190322649A1 (en) 2019-10-24
PT1409467E (en) 2012-10-24
US7196205B2 (en) 2007-03-27
US8779163B2 (en) 2014-07-15
LU92717I2 (en) 2015-11-24
BR122015016313B8 (en) 2021-05-25
ES2395463T4 (en) 2013-02-12
IL193244A0 (en) 2009-02-11
BR0211379A (en) 2004-08-17
US7265228B2 (en) 2007-09-04
EP2266968B1 (en) 2013-01-09
US7763738B2 (en) 2010-07-27
JP2017075151A (en) 2017-04-20
BR122015016314B1 (en) 2019-04-16
EP2067775A1 (en) 2009-06-10
ES2399323T3 (en) 2013-03-27
DK2266968T3 (en) 2013-04-08
CY2015028I2 (en) 2016-07-27
BR122015016314B8 (en) 2021-05-25
EP1409467A1 (en) 2004-04-21
US20050009872A1 (en) 2005-01-13
US20030050299A1 (en) 2003-03-13
JP2005502635A (en) 2005-01-27
EP2266968A2 (en) 2010-12-29
US20150148534A1 (en) 2015-05-28
US8138353B2 (en) 2012-03-20
PT2067775E (en) 2012-07-16
IL159905A (en) 2009-05-04
FR15C0036I2 (en) 2016-05-27
ES2395122T3 (en) 2013-02-08
HK1153733A1 (en) 2012-04-05
HK1132267A1 (en) 2010-02-19
US6855830B2 (en) 2005-02-15
WO2003008399A1 (en) 2003-01-30
JP5038582B2 (en) 2012-10-03
US20050222244A1 (en) 2005-10-06
JP5227348B2 (en) 2013-07-03
CA2453978A1 (en) 2003-01-30
BRPI0211379B1 (en) 2018-02-14
JP2015180656A (en) 2015-10-15
US20170334888A1 (en) 2017-11-23
US20080058514A1 (en) 2008-03-06
US20120296088A1 (en) 2012-11-22
US20110003987A1 (en) 2011-01-06
JP2005255686A (en) 2005-09-22
US20070203223A1 (en) 2007-08-30
BRPI0211379B8 (en) 2021-05-25
JP2010095546A (en) 2010-04-30
US7615573B2 (en) 2009-11-10

Similar Documents

Publication Publication Date Title
FR15C0036I1 (en)
AU2002348261A1 (en) Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
PT923554E (en) N-BENZYLPIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES
HRP20020997A2 (en) Serine protease inhibitors
NZ329532A (en) Diazepino-indoles as phosphodiesterase iv inhibitors
EP1385518A4 (en) Benzimidazolone compounds
IL132690A0 (en) Prostaglandin pharmaceutical compositions
AU5239700A (en) Process for the synthesis of n-(4-cyano-3-trifluoromethylphenyl)-3-(4-fluorophenyl-sulfon l)-2-hydroxy-2-methyl-propionamide
AU2003248647A1 (en) Stereoselective synthesis of 1,2-disubstituted cycloalkyls
AP9901698A0 (en) Novel process.
PL367774A1 (en) Synthesis and intermediates
MXPA03006057A (en) Process for preparing (plusmn;) trans-4 -p-fluorophenyl -3-hydroxymethyl -1-methylpiperidine.
IL139773A0 (en) Morphine-6-glucuronide synthesis
CY1113586T1 (en) A N-ACYLOSYFINGOUS Glycosyltransferase Suspension
SI1286965T1 (en) Piperidine compounds and process for providing such
IT1313665B1 (en) New production of 7-alpha-alkyl-17-beta-hydroxy-19-norpregn-5(10)-en-20-in-3-ones
NO20030876D0 (en) Process for racemization of 1-benzyl-4- (4-fluorophenyl) -3-hydroxymethyl-1,2,3,6-tetrahydropyridine for use as an intermediate in the synthesis of paroxetine